St. Jude Medical Announces Australian TGA Approval of Athena Programmer for the Management of Deep Brain Stimulation Therapy
January 24 2011 - 8:00AM
Business Wire
St. Jude Medical, Inc. (NYSE:STJ), a global medical device
company, today announced regulatory approval from the Australian
Therapeutic Goods Administration (TGA) of its Athena™ programmer, a
deep brain stimulation (DBS) therapy management system.
St. Jude Medical, Inc., a global medical
device company, has received regulatory approval from the
Australian Therapeutic Goods Administration (TGA) of its new
Athena(TM) programmer, a deep brain stimulation therapy management
system. The easy-to-use programmer with the largest and only
full-color touch screen allows clinicians to optimize deep brain
stimulation therapy through advanced programming and data
management features. Medical image provided by St. Jude Medical,
Inc.
This easy-to-use platform offers clinicians a powerful interface
that enables them to set or adjust deep brain stimulation
parameters to optimize each patient’s therapy. The system also has
the most comprehensive data management capacity of any DBS
programmer on the market, which aids clinicians in the organization
and storage of important patient information.
“The Athena programmer is an innovative new product designed to
help physicians manage the unique challenges associated with
programming deep brain stimulation systems,” said Chris Chavez,
president of the St. Jude Medical Neuromodulation Division. “We are
excited to be able to offer this programming platform to physicians
in Australia as part of our newly introduced family of deep brain
stimulation products.”
Designed as a tablet PC, the Athena programmer can be utilized
through an interactive touch screen or through a keyboard,
depending on the clinician’s preference. The system’s unique
features include:
- Measuring 22.6 cm, the Athena
programmer screen is the largest and only full-color touch screen,
which allows clinicians to see all lead and programming information
at one time
- Programmer’s database provides a full
history of programming sessions for up to 1,000 patients with 200
sessions for each patient
- Capability that permits data export for
analysis, printing, emailing and importing into electronic medical
records
- Programming session notes can be easily
accessed in subsequent sessions through a convenient notes
section
The Athena programmer is also approved in European Union
countries and is in the submission process for additional markets.
It can be used to program the Libra™, LibraXP™, and Brio™ DBS
systems which are also approved for use in Australia and European
Union countries.
Deep brain stimulation is used to manage the symptoms of
Parkinson’s disease, a neurological disorder that progressively
diminishes a person’s control over his or her movements and speech.
Parkinson’s disease affects an estimated 6.3 million people
worldwide, according to the European Parkinson’s Disease
Association.
For more than 30 years, the St. Jude Medical Neuromodulation
Division has developed new technologies to manage chronic pain and
other neurological disorders. Today more than 75,000 patients in 40
countries have been implanted with St. Jude Medical
neurostimulation systems.
About St. Jude Medical
St. Jude Medical develops medical technology and services that
focus on putting more control into the hands of those who treat
cardiac, neurological and chronic pain patients worldwide. The
company is dedicated to advancing the practice of medicine by
reducing risk wherever possible and contributing to successful
outcomes for every patient. St. Jude Medical is headquartered in
St. Paul, Minn. and has four major focus areas that include:
cardiac rhythm management, atrial fibrillation, cardiovascular and
neuromodulation. For more information, please visit sjm.com.
Forward-Looking Statements
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
that involve risks and uncertainties. Such forward-looking
statements include the expectations, plans and prospects for the
Company, including potential clinical successes, anticipated
regulatory approvals and future product launches, and projected
revenues, margins, earnings and market shares. The statements made
by the Company are based upon management’s current expectations and
are subject to certain risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include
market conditions and other factors beyond the Company’s control
and the risk factors and other cautionary statements described in
the Company’s filings with the SEC, including those described in
the Risk Factors and Cautionary Statements sections of the
Company’s Quarterly Report on Form 10-Q for the fiscal quarter
ended October 2, 2010. The Company does not intend to update
these statements and undertakes no duty to any person to provide
any such update under any circumstance.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6581931&lang=en
SJM (NYSE:STJ)
Historical Stock Chart
From May 2024 to Jun 2024
SJM (NYSE:STJ)
Historical Stock Chart
From Jun 2023 to Jun 2024